Clinical Trials
45 trialsKEYNOTE 975
Merck Sharp & Dohme LLC
KEYLYNK-001
Merck Sharp & Dohme LLC
GDFATHERHCC01
CatalYm GmbH
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
EXCELL
Grifols Therapeutics LLC
MAIA-ovarian
Compugen Ltd
KEYNOTE-B49
Merck Sharp & Dohme LLC
KEYNOTE-564
Merck Sharp & Dohme LLC
KEYNOTE-585
Merck Sharp & Dohme LLC
KEYNOTE-B96
Merck Sharp & Dohme LLC
KEYNOTE-585
Merck Sharp & Dohme LLC
KEYNOTE-826
Merck Sharp & Dohme LLC
Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma
Glonova Pharma Co., Ltd
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Hope Biosciences Research Foundation
V940-001
Merck Sharp & Dohme LLC
A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study
Medigen Biotechnology Corporation
KEYNOTE-641
Merck Sharp & Dohme LLC
KEYNOTE-921
Merck Sharp & Dohme LLC
PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
PhytoHealth Corporation
Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions
Nakafarma S.L.
ERA 223
Bayer
MK-3475-789
Merck Sharp & Dohme LLC
MK-3475-189
Merck Sharp & Dohme LLC
PRESERVE 2
G1 Therapeutics, Inc.
KEYNOTE-921
Merck Sharp & Dohme LLC
Cornerstone001
Aston Sci. Inc.
MK-3475-189
Merck Sharp & Dohme LLC
Capella
MitoImmune Therapeutics
AML
Jazz Pharmaceuticals
MK-7110-002
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cornerstone4
Aston Sci. Inc.
KEYNOTE-604
Merck Sharp & Dohme LLC
PANCRIT®-1
Gilead Sciences
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
CSL Behring
IRON CLAD
American Regent, Inc.
EFFIKIR
Innate Pharma
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
Merck Sharp & Dohme LLC
FAR-122
Morphotek
Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization
Achieve Life Sciences
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
Bristol-Myers Squibb
Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors
Alaunos Therapeutics
LucaVax
Kael-GemVax Co., Ltd.
Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)
Italfarmaco
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
Windy Hill Medical, Inc.